Literature DB >> 19248200

Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.

Ri-Nan Zheng1.   

Abstract

AIM: To clarify whether there is any difference in the symptom relief in patients with reflux esophagitis following the administration of four Proton pump inhibitors (PPIs).
METHODS: Two hundred and seventy-four patients with erosive reflux esophagitis were randomized to receive 8 wk of 20 mg omeprazole (n = 68), 30 mg of lansoprazole (n = 69), 40 mg of pantoprazole (n = 69), 40 mg of esomeprazole (n = 68) once a day in the morning. Daily changes in heartburn and acid reflux symptoms in the first 7 d of administration were assessed using a six-point scale (0: none; 1: mild; 2: mild-moderate; 3: moderate; 4: moderate-severe; 5: severe).
RESULTS: The mean heartburn score in patients treated with esomeprazole more rapidly decreased than those receiving other PPI. Complete resolution of heartburn was also more rapid in patients treated with esomeprazole for 5 d compared with omeprazole (P = 0.0018, P = 0.0098, P = 0.0027, P = 0.0137, P = 0.0069, respectively), lansoprazole (P = 0.0020, P = 0.0046, P = 0.0037, P = 0.0016, P = 0.0076, respectively), and pantoprazole (P = 0.0006, P = 0.0005, P = 0.0009, P = 0.0031, P = 0.0119, respectively). There were no significant differences between the four groups in the rate of endoscopic healing of reflux esophagitis at week 8.
CONCLUSION: Esomeprazole may be more effective than omeprazole, lansoprazole, and pantoprazole for the rapid relief of heartburn symptoms and acid reflux symptoms in patients with reflux esophagitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19248200      PMCID: PMC2653397          DOI: 10.3748/wjg.15.990

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

Authors:  M Besancon; A Simon; G Sachs; J M Shin
Journal:  J Biol Chem       Date:  1997-09-05       Impact factor: 5.157

2.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

Review 3.  Proton pump inhibitors and acid-related diseases.

Authors:  G Sachs
Journal:  Pharmacotherapy       Date:  1997 Jan-Feb       Impact factor: 4.705

4.  One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease.

Authors:  F Johnsson; L Weywadt; J H Solhaug; H Hernqvist; L Bengtsson
Journal:  Scand J Gastroenterol       Date:  1998-01       Impact factor: 2.423

5.  Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease.

Authors:  Kerstin Röhss; Göran Hasselgren; Hans Hedenström
Journal:  Dig Dis Sci       Date:  2002-05       Impact factor: 3.199

6.  The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis.

Authors:  R Fass; J J Ofman; R E Sampliner; L Camargo; C Wendel; M B Fennerty
Journal:  Aliment Pharmacol Ther       Date:  2000-04       Impact factor: 8.171

7.  Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease.

Authors:  E Dimenäs; G Carlsson; H Glise; B Israelsson; I Wiklund
Journal:  Scand J Gastroenterol Suppl       Date:  1996

8.  Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease.

Authors:  C Winters; T J Spurling; S J Chobanian; D J Curtis; R L Esposito; J F Hacker; D A Johnson; D F Cruess; J D Cotelingam; M S Gurney
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

9.  Methodological aspects of evaluation of Quality of Life in upper gastrointestinal diseases.

Authors:  E Dimenäs
Journal:  Scand J Gastroenterol Suppl       Date:  1993

10.  Are esophageal symptoms reflux-related? A study of different scoring systems in a cohort of patients with heartburn.

Authors:  B T Johnston; J S Collins; R J McFarland; A H Love
Journal:  Am J Gastroenterol       Date:  1994-04       Impact factor: 10.864

View more
  9 in total

1.  Stress ulcer prophylaxis guidelines: Are they being implemented in Lebanese health care centers?

Authors:  Abeer Zeitoun; Maya Zeineddine; Hani Dimassi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2011-08-06

2.  Relationship Between Gastroesophageal Reflux Disease and Endoscopic Finding "Iodine-Unstained Streak".

Authors:  Kazu Hamada; Tohru Itoh; Ken Kawaura; Hidekazu Kitakata; Hiroaki Kuno; Junji Kamai; Rika Kobayasi; Sadahumi Azukisawa; Taishi Ishisaka; Yuta Igarashi; Kumie Kodera; Tazuo Okuno; Takuro Morita; Taroh Himeno; Hiroshi Yano; Toshihiro Higashikawa; Osamu Iritani; Kunimitsu Iwai; Shigeto Morimoto; Masashi Okuro
Journal:  J Clin Med Res       Date:  2020-11-03

3.  Gastroesophageal reflux disease after diagnostic endoscopy in the clinical setting.

Authors:  Nora B Zschau; Jane M Andrews; Richard H Holloway; Mark N Schoeman; Kylie Lange; William Ce Tam; Gerald J Holtmann
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

4.  A randomized, crossover pharmacodynamic study of immediate-release omeprazole/sodium bicarbonate and delayed-release lansoprazole in healthy adult volunteers.

Authors:  Vijayalakshmi S Pratha; Thomas McGraw; William Tobin
Journal:  Pharmacol Res Perspect       Date:  2016-05-19

Review 5.  The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease.

Authors:  Anita Gąsiorowska
Journal:  Prz Gastroenterol       Date:  2017-12-14

6.  Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms.

Authors:  Morton Scheinberg; Henrique Pott Júnior; Eduardo de Almeida Macêdo; Monalisa Fernanda Bocchi de Oliveira; Christina Ecclissato; Roberto Bleuel Amazonas
Journal:  Drug Des Devel Ther       Date:  2018-09-06       Impact factor: 4.162

Review 7.  Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker.

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  J Neurogastroenterol Motil       Date:  2019-01-31       Impact factor: 4.924

8.  Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.

Authors:  Kwang Jae Lee; Byoung Kwan Son; Gwang Ha Kim; Hye-Kyung Jung; Hwoon-Yong Jung; Il-Kwun Chung; In-Kyung Sung; Jin Il Kim; Jong Hyeok Kim; Joon Seong Lee; Joong Goo Kwon; Jung Ho Park; Kyu Chan Huh; Kyung Sik Park; Moo-In Park; Nayoung Kim; Oh Young Lee; Sam Ryong Jee; Sang Kil Lee; Sei Jin Youn; Sung Kook Kim; Soo Teik Lee; Su Jin Hong; Suck Chei Choi; Tae Nyeun Kim; Young Hoon Youn; Hyo Ju Park; Min Ja Kang; Chi Hye Park; Bong Tae Kim; Sangjun Youn; Geun Seog Song; Poong-Lyul Rhee
Journal:  Aliment Pharmacol Ther       Date:  2019-03-06       Impact factor: 8.171

9.  Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.

Authors:  Yinglian Xiao; Shutian Zhang; Ning Dai; Guijun Fei; Khean-Lee Goh; Hoon Jai Chun; Bor-Shyang Sheu; Chui Fung Chong; Nobuo Funao; Wen Zhou; Minhu Chen
Journal:  Gut       Date:  2019-08-13       Impact factor: 23.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.